Breaking News

Tweet TWEET

Amarin to Present at the CITI 2013 Global Healthcare Conference

Amarin to Present at the CITI 2013 Global Healthcare Conference

BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 21, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced that Joseph Zakrzewski, Amarin's Chairman and
Chief Executive Officer, is scheduled to present a general company update at
the CITI 2013 Global Healthcare Conference on Wednesday, February 27, 2013, at
3:00 p.m. ET. This conference will be held at the Hilton New York Hotel in New
York City.

A live audio webcast of the presentation will be available at:

http://www.veracast.com/webcasts/citigroup/healthcare2013/68309238.cfm

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's
firstFDAapproved product, is a patented, ultra pure omega-3 fatty acid
product comprising not less than 96%EPA and is available by prescription. For
more information about Vascepa visit www.vascepa.com. For more information
about Amarin visit www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

CONTACT: Amarin contact information:
         Stephen Schultz or Joseph Bruno
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.